PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Diagnostic relevance of a novel multiplex immunoassay panel in breast cancer.

Abstract Multiple factors contribute to the development and progression of breast cancer. Markers of tumor growth and invasion, cell death, immune activation, and angiogenesis can be assessed in parallel by a novel multiplex immunoassay panel. The diagnostic performance of a multiplex cancer biomarker magnetic bead panel comprising 24 tumor associated parameters was evaluated in sera of 154 women including 77 patients with breast cancer, 10 with precancerous lesions, 31 with benign breast diseases, and 36 healthy controls. Marker levels were log-transformed for variance stabilization. Significance testing was done using t-test or Wilcoxon rank-sum test with correction of p values for multiple testing. Furthermore, receiver operating characteristic analyses were performed. Serum levels of several biomarkers were significantly (p ≤ 0.001) higher in cancer patients than in healthy controls, particularly alpha-fetoprotein, cancer antigen 15-3, cancer antigen 19-9, migration inhibitory factor, carcinoembryonic antigen, cancer antigen 125, hepatocyte growth factor, soluble Fas, tumor necrosis factor-α, stem cell factor, and osteopontin. As most markers were also elevated in benign breast diseases, only cancer antigen 15-3 showed significant differences to cancer patients (p ≤ 0.001). The resulting areas under the curve in receiver operating characteristic curves for discrimination between benign and malignant breast diseases achieved 0.71 with a sensitivity of 33.8% at 95% specificity. Multiplexing enables parallel analysis of different biomarker classes for cancer detection. Established cancer antigen 15-3 proved to be most relevant for differential diagnosis.
PMID
Related Publications

Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).

Clinical Performance of CEA, CA19-9, CA15-3, CA125 and AFP in Gastrointestinal Cancer Using LOCI™-based Assays.

The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.

Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer.

A bead-based multiplexed immunoassay to evaluate breast cancer biomarkers for early detection in pre-diagnostic serum.

Authors

Mayor MeshTerms

Diagnosis, Differential

Keywords

Breast cancer

biomarker

multiplex immunoassay

tumor marker

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28618926
OWN - NLM
STAT- MEDLINE
DA  - 20170616
DCOM- 20170622
LR  - 20170622
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 6
DP  - 2017 Jun
TI  - Diagnostic relevance of a novel multiplex immunoassay panel in breast cancer.
PG  - 1010428317711381
LID - 10.1177/1010428317711381 [doi]
AB  - Multiple factors contribute to the development and progression of breast cancer. 
      Markers of tumor growth and invasion, cell death, immune activation, and
      angiogenesis can be assessed in parallel by a novel multiplex immunoassay panel. 
      The diagnostic performance of a multiplex cancer biomarker magnetic bead panel
      comprising 24 tumor associated parameters was evaluated in sera of 154 women
      including 77 patients with breast cancer, 10 with precancerous lesions, 31 with
      benign breast diseases, and 36 healthy controls. Marker levels were
      log-transformed for variance stabilization. Significance testing was done using
      t-test or Wilcoxon rank-sum test with correction of p values for multiple
      testing. Furthermore, receiver operating characteristic analyses were performed. 
      Serum levels of several biomarkers were significantly (p </= 0.001) higher in
      cancer patients than in healthy controls, particularly alpha-fetoprotein, cancer 
      antigen 15-3, cancer antigen 19-9, migration inhibitory factor, carcinoembryonic 
      antigen, cancer antigen 125, hepatocyte growth factor, soluble Fas, tumor
      necrosis factor-alpha, stem cell factor, and osteopontin. As most markers were
      also elevated in benign breast diseases, only cancer antigen 15-3 showed
      significant differences to cancer patients (p </= 0.001). The resulting areas
      under the curve in receiver operating characteristic curves for discrimination
      between benign and malignant breast diseases achieved 0.71 with a sensitivity of 
      33.8% at 95% specificity. Multiplexing enables parallel analysis of different
      biomarker classes for cancer detection. Established cancer antigen 15-3 proved to
      be most relevant for differential diagnosis.
FAU - Hermann, Natalie
AU  - Hermann N
AD  - 1 Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital 
      Bonn, Bonn, Germany.
FAU - Dressen, Katja
AU  - Dressen K
AD  - 1 Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital 
      Bonn, Bonn, Germany.
FAU - Schroeder, Lars
AU  - Schroeder L
AD  - 2 Department of Gynecology and Obstetrics, University Hospital Bonn, Bonn,
      Germany.
AD  - 3 Center for Integrated Oncology (CIO) Koln/Bonn, Koln, Germany.
FAU - Debald, Manuel
AU  - Debald M
AD  - 2 Department of Gynecology and Obstetrics, University Hospital Bonn, Bonn,
      Germany.
AD  - 3 Center for Integrated Oncology (CIO) Koln/Bonn, Koln, Germany.
FAU - Schildberg, Frank A
AU  - Schildberg FA
AD  - 4 Institutes of Molecular Medicine and Experimental Immunology, University
      Hospital Bonn, Bonn, Germany.
FAU - Walgenbach-Bruenagel, Gisela
AU  - Walgenbach-Bruenagel G
AD  - 1 Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital 
      Bonn, Bonn, Germany.
AD  - 3 Center for Integrated Oncology (CIO) Koln/Bonn, Koln, Germany.
FAU - Hettwer, Karina
AU  - Hettwer K
AD  - 5 QuoData Statistics, Dresden, Germany.
AD  - 6 Joint Research and Services Center for Biomarker Evaluation in Oncology, Bonn, 
      Germany.
FAU - Uhlig, Steffen
AU  - Uhlig S
AD  - 5 QuoData Statistics, Dresden, Germany.
AD  - 6 Joint Research and Services Center for Biomarker Evaluation in Oncology, Bonn, 
      Germany.
FAU - Kuhn, Walther
AU  - Kuhn W
AD  - 2 Department of Gynecology and Obstetrics, University Hospital Bonn, Bonn,
      Germany.
AD  - 3 Center for Integrated Oncology (CIO) Koln/Bonn, Koln, Germany.
FAU - Hartmann, Gunther
AU  - Hartmann G
AD  - 1 Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital 
      Bonn, Bonn, Germany.
AD  - 3 Center for Integrated Oncology (CIO) Koln/Bonn, Koln, Germany.
FAU - Holdenrieder, Stefan
AU  - Holdenrieder S
AD  - 1 Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital 
      Bonn, Bonn, Germany.
AD  - 3 Center for Integrated Oncology (CIO) Koln/Bonn, Koln, Germany.
AD  - 6 Joint Research and Services Center for Biomarker Evaluation in Oncology, Bonn, 
      Germany.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CA-125 Antigen)
RN  - 0 (CA-19-9 Antigen)
RN  - 0 (Carcinoembryonic Antigen)
RN  - 0 (MUC16 protein, human)
RN  - 0 (Membrane Proteins)
RN  - 0 (Mucin-1)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (alpha-Fetoproteins)
RN  - 106441-73-0 (Osteopontin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*blood
MH  - Breast Neoplasms/*blood/pathology
MH  - CA-125 Antigen/blood
MH  - CA-19-9 Antigen/blood
MH  - Carcinoembryonic Antigen/blood
MH  - *Diagnosis, Differential
MH  - Female
MH  - Humans
MH  - Immunoassay
MH  - Membrane Proteins/blood
MH  - Middle Aged
MH  - Mucin-1/*blood
MH  - Neoplasm Staging
MH  - Neoplasms/*blood/pathology
MH  - Osteopontin/blood
MH  - Tumor Necrosis Factor-alpha/blood
MH  - alpha-Fetoproteins/biosynthesis
OTO - NOTNLM
OT  - Breast cancer
OT  - biomarker
OT  - multiplex immunoassay
OT  - tumor marker
EDAT- 2017/06/18 06:00
MHDA- 2017/06/24 06:00
CRDT- 2017/06/17 06:00
AID - 10.1177/1010428317711381 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Jun;39(6):1010428317711381. doi: 10.1177/1010428317711381.